Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Cell Anatomy
Temporal Trends In Lipoprotein(A) Concentrations: The Atherosclerosis Risk In Communities Study, Matthew R. Deshotels, Caroline Sun, Vijay Nambi, Salim S. Virani, Kunihiro Matsushita, Bing Yu, Christie . M. Ballantyne, Ron C. Hoogeveen
Temporal Trends In Lipoprotein(A) Concentrations: The Atherosclerosis Risk In Communities Study, Matthew R. Deshotels, Caroline Sun, Vijay Nambi, Salim S. Virani, Kunihiro Matsushita, Bing Yu, Christie . M. Ballantyne, Ron C. Hoogeveen
Office of the Provost
Background: Plasma lipoprotein(a) (Lp[a]) concentrations are primarily determined by genetic factors and are believed to remain stable throughout life. However, data are scarce on longitudinal trends in Lp(a) concentrations over time. Therefore, it is unclear whether measurement of Lp(a) once in a person's life is sufficient for cardiovascular risk assessment in all adults.
Methods and Results: Lp(a) concentrations, specifically apolipoprotein(a) concentrations, were measured at visits 4 and 5, ≈15 years apart, in 4734 adult participants of the ARIC (Atherosclerosis Risk in Communities) study (mean age at visits 4 and 5, 60.7±5.1 and 75.5±5.2 years, respectively). Participants were categorized by baseline …
Phase I Trial Of The Murine Monoclonal Anti-Gd2 Antibody 14g2a In Metastatic Melanoma, Mansoor Saleh, M B. Khazaeli, Richard Wheeler, Edward Dropcho, Tiepu Liu, Marshall Urist, Donald Miller, Sharon Lawson, Pam Dixon, Charles Russell
Phase I Trial Of The Murine Monoclonal Anti-Gd2 Antibody 14g2a In Metastatic Melanoma, Mansoor Saleh, M B. Khazaeli, Richard Wheeler, Edward Dropcho, Tiepu Liu, Marshall Urist, Donald Miller, Sharon Lawson, Pam Dixon, Charles Russell
Haematology and Oncology, East Africa
In a phase I trial, 12 patients with GD2 antigen-positive metastatic melanoma received the murine anti-GD2 monoclonal antibody 14G2a. The monoclonal antibody was administered in four doses over an 8-day period with total dose ranging from 10 to 120 mg. All patients receiving >10 mg of 14G2a experienced transient abdominal/pelvic pain during the antibody infusion. Five patients had a delayed extremity pain syndrome following the third and fourth antibody infusion. Four of the five patients developed neurological toxicity, including two patients with significant although reversible motor neuropathy. Two of the patients developed hyponatremia secondary to a syndrome of …
Monocyte-Platelet Interaction In Immune And Nonimmune Thrombocytopenia, Mansoor Saleh, D L. Moore, J Y. Lee, A F. Lobuglio
Monocyte-Platelet Interaction In Immune And Nonimmune Thrombocytopenia, Mansoor Saleh, D L. Moore, J Y. Lee, A F. Lobuglio
Haematology and Oncology, East Africa
Platelets from 24 patients with immune thrombocytopenia resistant to standard therapy (refractory ITP), 35 patients with nonimmune thrombocytopenia (non-ITP), and 32 normal donors were studied in regard to platelet surface-bound IgG (PBIgG) and the ability of these platelets to be bound by human monocytes in vitro (monocyte-platelet rosette assay). Fourteen (58%) of the platelet samples from refractory ITP patients but none (0%) from the non-ITP or control donors had PBIgG greater than 800 molecules IgG/platelet. Seventeen of 24 (71%) of the ITP patients had platelets which demonstrated increased monocyte- platelet rosette formation [rosette index (RI) greater than 2], whereas only …
Effect Of Intravenous Gammaglobulin On Circulating And Platelet-Bound Antibody In Immune Thrombocytopenia, G Garbano, Mansoor Saleh, P G. Mori, A F. Lobuglio, D Shaw
Effect Of Intravenous Gammaglobulin On Circulating And Platelet-Bound Antibody In Immune Thrombocytopenia, G Garbano, Mansoor Saleh, P G. Mori, A F. Lobuglio, D Shaw
Haematology and Oncology, East Africa
Ten patients with idiopathic thrombocytopenic purpura (ITP) were studied before and following a rise in circulating platelets subsequent to infusions of intravenous gammaglobulin (400 mg/kg/day x 5 days). We quantitated the amount of circulating IgG capable of binding to normal donor platelets in vitro using an 125I-monoclonal anti-human IgG assay, as well as the amount of IgG associated with the patients' platelets before and following therapy. We found no evidence for a decrease in platelet-specific IgG antibodies in these patients undergoing an acute response to therapy. These data suggest that the short-term efficacy of intravenous gammaglobulin is due to effects …